Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN.
Apr 30 2013Journal of Clinical Endocrinology & Metabolism Publishes Positive Versartis Phase I Data
Jan 15 2013
Versartis Closes $25 Million Series C Financing Oct 24 2012
Versartis Initiates VERTICAL Trial of Long Acting Human Growth Hormone in Children with Growth Hormone Deficiency